BOI Bank Irel13.375

RNS Number:3379X
Biotrace International PLC
24 January 2006

For Immediate Release                                            24 January 2006

                           BIOTRACE INTERNATIONAL PLC
                                                                                
                                 Trading Update

Biotrace International Plc ("Biotrace", "the Company" or "the Group"), a leading
manufacturer of industrial microbiology and life science products, is pleased to
update investors with the following trading statement:

Strong revenue growth was achieved across all divisions in 2005 despite
difficult trading conditions in the food sector. Good progress was made in the
core Industrial business, which benefited from a full year's contribution by
Tecra, acquired in June 2004 and through the acquisition in September 2005 of
MicroSafe. As anticipated, the Defence and Life Science businesses remained at
similar levels to the previous year, before the addition of new business
acquired with MicroSafe.

Biotrace continues to benefit from the high level of repeat consumable revenues
which remained above 90% of Group revenues in 2005. This, together with a
similarly high level of sales generated from own brands and direct selling,
provides the Company with high visibility of future earnings and is a solid
platform for sales growth in 2006.

Ian Johnson, Chief Executive Officer of Biotrace, said:

"I am pleased to report that the Group continued to make good progress in 2005
and is likely to report year end results in line with market expectations.

Biotrace continues to be a profitable, highly cash generative business with
significant growth potential. The recently announced collaboration with Pall
Corporation is a great endorsement of our proprietary technologies and will help
expand our business in the attractive pharmaceutical market.

I am optimistic about the Group's prospects and look forward to building on our
achievements in the coming year."

Biotrace will announce its preliminary results for the year to 31 December 2005
on Wednesday 1 March 2006. There will be a presentation to analysts on the day
at 09.30, held at the offices of Buchanan Communications, 45 Moorfields, London
EC2Y 9AE.

                                    - ENDS -

For further information, please contact:

Biotrace International Plc
Ian Johnson, Chief Executive Officer               Tel: +44 (0)1656 641 400
Peter Morgan, Finance Director

Buchanan Communications
Tim Anderson/James Strong                          Tel: +44 (0)20 7466 5000

Notes to editors:

Biotrace International Plc is a leading manufacturer and supplier of industrial
microbiology and life science products. The Company is organised into three
business segments: Industrial, Life Sciences and Defence. The Group's
proprietary technologies are used by most of the world's leading food and
beverage manufacturers who rely on Biotrace products as an essential part of
their quality control procedures. Industrial customers also include
pharmaceutical industries, personal care product manufacturers and environmental
water markets. The Life Sciences business manufactures highly specialised
workstations for hospital microbiology laboratories and medical research
organisations. The Defence segment provides systems and consumables for the
rapid detection of biological weapons.

Formed in 1988 and floated on the London Stock Exchange in 1993, Biotrace had
total revenues of #27 million in 2004. The Company is headquartered in Bridgend,
UK with manufacturing and sales operations worldwide. Visit Biotrace at
www.biotrace.com



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
TSTFGGZMRFNGVZM

Bank Irel13.375 (LSE:BOI)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Bank Irel13.375 (LSE:BOI)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024